Brief: Pulse Biosciences Announces FDA 510(K) Clearance For The Treatment Of Sebaceous Hyperplasia
26/09/2022 13:27
Sept 26 (Reuters) - Pulse Biosciences Inc PLSE.O :
* PULSE BIOSCIENCES ANNOUNCES FDA 510(K) CLEARANCE FOR THE
TREATMENT OF SEBACEOUS HYPERPLASIA
Source text for Eikon: ID:nBw7FjDZya
Further company coverage: PLSE.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Pulse Biosciences
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Pulse Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Pulse Biosciences Q2 net loss widens, cash position strengthens
Pulse Biosciences Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants